The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1 site in 1 country1,200 target enrollmentMay 30, 2023

ConditionsBladder Cancer Radiomics Immunotherapy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Bladder Cancer
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Enrollment: 1200
Locations: 1
Primary Endpoint: Tumour-infiltrating lymphocytes (TIL)
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The aim of this study was to develop an radiomic model based on CT images to evaluate markers of the bladder cancer microenvironment, such as TSR,TIL, and IP. Secondly, the association of the radiomic model with clinical outcomes and immunotherapy response was investigated.

Registry

clinicaltrials.gov

Start Date

May 30, 2023

End Date

February 20, 2024

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•At least 18 years of age;
•Performing TURB-t or RC during 2010-2022;
•The primary lesion was located in the bladder, and the pathological diagnosis was urothelial carcinoma;
•Complete clinical information, pathological data, preoperative pelvic enhanced CT and follow-up records;

Exclusion Criteria

•Patients with distant metastasis;
•Combined with other malignant tumors or malignant tumor treatment history
•Malignant tumors of upper urinary tract;
•Clinical information, pathological data, preoperative pelvic enhanced CT and follow-up records were missing;
•Other situations in which the researcher considers it inappropriate to participate in this study.